down

Managing Preanalytical Processes for Patient Safety

...mple-to-use patient ID systems. The decision boils down to features and cost. So how do you determine whic...els to be placed correctly on the tube (vertically down the side as opposed to spiral around the tube or attached like a flag waving in the breeze)? Does...

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

...rome. Other analyses physically separate and break down lipoproteins. The SPIFE Lipoprotein analyzer (Helena Laboratories) offers lipoprotein phenotypingseparating lipoproteins into alpha, pre-beta and beta lipoproteins, as well as chylomicrons. Beyond identifying risk, a patients lipoprotein distribut...

Hematology Analyzers Simple, Sophisticated Technology Serving All Patients

...nges, resulting in more reliable performance, less down time, and simpler repairs. Visible wavelength light is passed through the sample stream in even the simplest modern hematology analyzers. In most cell counters, the resulting light scatter is used to classify cells by granularity. Visible wavelength ...

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

...tro data and suggestsCaprospinol may not only slow down Alzheimer's but may also reverseplaque-related brain injuries associated with the mind-robbingdisease of Alzheimer's. The hallmark of Alzheimer's disease is plaque formation in areasof the brain that control memory and thinking skills. Plaque cancau...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

...tial for a newindication for Proellex. We are well down the road of preparing acomplete dossier for NDA submission for Proellex in the treatmentof uterine fibroids, which is expected around the end of 2008.Though not a trivial task, this new indication could be developedwith a specific focus on efficacy q...

Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target

...gon-Like Peptide-1(GLP-1), which is rapidly broken down in the body and thus notpractical as a therapy for type 2 diabetes. GLP-1 is released fromthe gastrointestinal tract upon ingestion of food. When glucoselevels become too high, GLP-1 triggers the release of insulin fromthe pancreas and decreases the ...

Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint

...alyzed to-date.Neoprobe now plans to begin winding down Phase 2 trial activities,collecting the required 30-day patient safety follow-up informationand accumulating data to report to FDA. In parallel, Neoprobe isalso preparing to submit its Phase 3 pivotal trial protocol toFDA. About Neoprobe Neoprobe i...

Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting

...07, asits Chairman. Mr. Stephen G. Sudovar stepped down as a member ofthe Board and as its Executive Chairman, as well as interim ChiefExecutive Officer of the Company, for personal reasons. The searchfor a new President and Chief Executive Officer is still ongoing.Ambrilia's day-to-day operations continu...

Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis

...ents (RAMBAs),which inhibit the body from breaking down its own retinoic acid,the active form of vitamin A, a key nutrient for healthy skin.While Barrier has no plans to further develop this productcandidate itself, we intend to provide the data to U.S. andEuropean regulatory authorities and to companies ...

Dynogen Reports Positive Results in Phase 1B GERD Study

...occurrence of GERD at night, typically while lying down to sleep.Symptoms associated with stomach reflux are exacerbated by the lackof assistance from gravity while lying recumbent. NGERD is commonlyassociated with a higher risk and a higher degree of esophagitis;acid remains in the esophagus for prolonge...

Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia

...e 2attached, there was a statistically significant down regulation ofBcl-2 mRNA (expressed as a ratio to 18S ribosomal RNA, a measure oftotal blood RNA) in patients receiving drug at 4mg/kg/infusion,over the 2 week course of therapy. Such patient data supports theview that SPC2996 is working through speci...

Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer

...s almost100%. But if it has spread, that rate goes down dramatically to33%. For full prescribing information, including boxed WARNING, call800-633- 1610 or visit <a target="_blank" href="http://www.taxotere.com/">www.taxotere.com . About sanofi-aventis Sanofi-aventis is one of the world leaders...

OXiGENE Abstracts Published in ASCO Program

...earch with OXi4503 suggests that it not only shuts down tumorblood flow, but can also be metabolized into a compound which couldassist with killing the remaining tumor cells at the periphery ofthe tumor by direct cytotoxic activity against tumor cells. InDecember 2004, the United Kingdom regulatory author...

Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data

... best practices and performance metrics. To drill down on the numerous metrics presented in this reportmore deeply contact our Solution Specialists at (919) 403-0251 or .<a target="_blank" href="mailto:bestpractices@best-in-class.com">bestpractices@best-in-class.com ABOUT BEST PRACTICES, LLC B...

Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis

...e subsequent inflammatory process should be slowed down and thedeterioration of skin or other tissues reduced. For further information please contact: Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren Claudine Blaser, PhD Director Corporate Communications Tel.: +41 44 733 47 20 e-Mail: <a tar...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

...hieve the randomized dose. Then, doses weretapered down weekly so that all participants randomized to GXRreceived the 1 mg dose at week eight. Participants achieved overall significant mean reductions frombaseline in ADHD-RS-IV total scores by study end, -16.7 points vs.-8.9 for placebo (P <.0001). I...

Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''

...EGUS? COPEGUS is a medicine that works by slowing down the growth ofthe virus. COPEGUS should be taken with PEGASYS to fight the virus.Do not take COPEGUS by itself. COPEGUS (Ribavirin, USP) can be extremely harmful and causebirth defects in an unborn baby. Female patients and the femalepartners of male...

Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron

...EGUS? COPEGUS is a medicine that works by slowing down the growth ofthe virus. COPEGUS should be taken with PEGASYS to fight the virus.Do not take COPEGUS by itself. COPEGUS (Ribavirin, USP) can be extremely harmful and causebirth defects in an unborn baby. Female patients and the femalepartners of male...

Quest PharmaTech's Prostate Cancer Program Update

...d post PDT treatment, highlighted thecomplete shut down of metabolic activity at the tumor site 24 hoursafter PDT treatment. The practical application of this new PDT treatment system onthe prostate gland has also been demonstrated using a canineprostate model. The intra-arterial drug delivery system a...

Schepens Scientists Identify Key to Integrating Transplanted Nerve Cells Into Injured Tissue

... is induced bystem cells) has the ability to break down barriers on the outersurface of a damaged retina and allow healthy donor cells tointegrate and wire themselves into remaining recipient tissue. Thefinding, reported in the current issue (April 25, 2007) of theJournal of Neuroscience, holds great prom...

Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference

... is elevated in a wide range of tumors,and through down regulation can cooperate with a variety ofcellular cancer causing genes known as oncogenes to enhance tumorgrowth and metastatic potential. About siRNA siRNA is a novel class of molecules that can decrease cellulartarget RNA expression through an a...

Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting

...le targets in endogenousapoptosis pathways to shut down cell growth and proliferation incancer cells. For additional information on Ascenta Therapeutics, please visitthe company's website at www.ascenta.com. Contact Ascenta Therapeutics, Inc. Mark Benedyk PhD Vice President, Business Development 858-43...

Sarasota's Roskamp Institute Announces Positive Safety Data in Human Clinical Study for Alzheimer's Disease

... at whether this drug is going tobe useful to slow down or prevent this dreadful disease." Dr.Mullan added. The Roskamp Institute is devoted to understanding causes of, andfinding cures for, diseases of the mind like neuropsychiatric andneurodegenerative disorders and addictions. The Institute utilizesa ...

Protein Found to Shield Pancreatic Cancer Cells from Self-Destruction

...ule known as smallinterfering RNA tailored to shut down expression of theprotein. In both cases, the result was a drastic reduction of TG2expression (up to 94 percent) and telltale signs of autophagy inthe cancer cells, which became riddled with cavities calledvacuoles. When autophagy occurs, a double m...

Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease

...mpartments in the cell where it is needed to break down GL-3. At the ACMG meeting, Amicus scientists will present data fromseveral studies that examined the in vitro and in vivo effects ofAmigal in cell lines, mice and healthy volunteers. Among the keyfindings: - In vitro exposure to Amigal increa...